SEC Comment Letter for NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509) — Feb 22, 2022
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: Feb. 22, 2022 · CIK: 0000810509 · Accession: 0000000000-22-002038
AI Filing Summary & Sentiment
File numbers found in text: 333-262691
Letter
United States securities and exchange commission logo February 22, 2022 Michael S. Rosol, Ph.D. Chief Medical Officer Navidea Biopharmaceuticals, Inc. 4995 Bradenton Avenue, Suite 240 Dublin, Ohio 43017 Re:Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-1 Filed February 14, 2022 File No. 333-262691 Dear Dr. Rosol: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William M. Mower, Esq.
Show Raw Text
United States securities and exchange commission logo
February 22, 2022
Michael S. Rosol, Ph.D.
Chief Medical Officer
Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue, Suite 240
Dublin, Ohio 43017
Re:Navidea Biopharmaceuticals, Inc.
Registration Statement on Form S-1
Filed February 14, 2022
File No. 333-262691
Dear Dr. Rosol:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William M. Mower, Esq.